V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160012000 | 160005719 | 1.66 | 60 | Palliative (P) | 2018-03-25 | 2018-04-02 | Olaratumab | 02 | N | IPILIMUMAB + NIVOLUMAB | 101413571 |
| 160012001 | 160005720 | 1.75 | 70.9 | Palliative (P) | 2019-02-01 | 2019-02-05 | EW EuroEwing 2012 Arm B VDC | 02 | N | CYCLOPHOSPHAMIDE + THALIDOMIDE | 101442262 |
| 160012002 | 160005721 | 0 | 8.9 | Palliative (P) | 2020-02-20 | 2020-02-24 | VIDE | 02 | Y | PACLITAXEL | 100305802 |
| 160012006 | 160005722 | 0 | 41.6 | Palliative (P) | 2018-10-01 | 2018-10-03 | Liposomal Doxorubicin (Caelyx) | N | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100449654 |
| 160012007 | 160005723 | 1.52 | 104.6 | Palliative (P) | 2016-11-16 | 2017-01-11 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101083463 |
| 160012009 | 160005724 | 1.44 | 69.8 | Palliative (P) | 2015-09-14 | 2015-09-28 | Doxorubicin + Ifosfamide | 02 | N | TRIAL UNSPECIFIED | 100115978 |
| 160012011 | 160005725 | 1.71 | 75.3 | Curative (C) | 2016-06-21 | 2016-06-29 | null | N | N | NOT MATCHED | 100722242 |
| 160012012 | 160005726 | 1.75 | 85.25 | Palliative (P) | null | 2018-07-05 | NB HRNBL-1 COJEC Ind COURSE A | 02 | N | CARBOPLATIN | 100982702 |
| 160012017 | 160005727 | 1.75 | 78.9 | null | 2020-09-03 | 2020-09-03 | Liposomal Doxorubicin 40mg/m2 | N | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101221753 |
| 160012020 | 160005728 | 1.6 | 58.1 | Palliative (P) | 2018-08-10 | 2018-08-15 | EW EuroEwing 2012 Arm B VDC | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100687179 |
| 160012021 | 160005729 | 1.72 | 106 | Palliative (P) | 2019-10-15 | 2019-10-22 | Doxorubicin + Ifosfamide | N | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101507800 |
| 160012022 | 160005730 | 1.8 | 87.2 | Curative (C) | 2016-02-20 | 2016-05-23 | Doxorubicin + Olaratumab | null | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100404293 |
| 160012025 | 160005732 | 1.22 | 73.6 | null | 2017-11-28 | 2017-12-11 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 101180944 |
| 160012026 | 160005733 | 1.79 | 97.85 | Curative (C) | 2016-12-28 | 2016-12-28 | Liposomal Doxorubicin (Caelyx) | N | N | NOT MATCHED | 101605597 |
| 160012027 | 160005734 | 1.5 | null | Curative (C) | 2017-05-11 | 2017-05-17 | PACLITAXEL | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101197961 |
| 160012028 | 160005735 | 1.65 | 61.8 | Curative (C) | 2018-12-25 | 2019-01-01 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100754976 |
| 160012031 | 160005736 | 1.78 | 75 | Neo-adjuvant (N) | 2016-02-17 | 2016-02-24 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101504133 |
| 160012034 | 160005737 | 1.69 | 89 | Palliative (P) | 2016-10-27 | 2016-10-27 | Pemetrexed | 02 | N | VINORELBINE | 100918514 |
| 160012038 | 160005738 | 1.66 | 62.9 | Neo-adjuvant (N) | 2016-05-17 | 2016-05-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100765298 |
| 160012039 | 160005739 | null | null | Neo-adjuvant (N) | 2019-05-13 | 2019-05-17 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100134125 |
| 160012040 | 160005740 | 1.71 | 69.7 | Palliative (P) | 2017-03-24 | 2017-04-07 | CYCLO + DOXORUBICIN + VINCRISTINE | 02 | N | PACLITAXEL | 100477717 |
| 160012041 | 160005741 | 1.61 | 57.2 | Palliative (P) | null | 2016-09-09 | IBRUTINIB | N | null | VIDE | 100398335 |
| 160012042 | 160005742 | 0 | 14 | 03 | 2017-03-10 | 2017-03-10 | Doxorubicin + Olaratumab | 02 | null | LIPOSOMAL DOXORUBICIN | 101758407 |
| 160012043 | 160005743 | 1.58 | 45.8 | Palliative (P) | 2017-04-30 | 2017-05-05 | Cisplatin + Pemetrexed | Y | N | CISPLATIN + PEMETREXED | 100641624 |
| 160012044 | 160005744 | 1.82 | 68 | Palliative (P) | null | 2019-10-11 | Cisplatin + Pemetrexed | N | null | CISPLATIN + PEMETREXED | 101477676 |
| 160012049 | 160005745 | 0 | 13.2 | Palliative (P) | null | 2021-01-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100738452 |
| 160012050 | 160005746 | 1.74 | 79 | Curative (C) | 2017-05-22 | 2017-05-30 | Doxorubicin 75mg/m2 | N | N | DOXORUBICIN | 100521574 |
| 160012051 | 160005747 | 1.52 | 84 | Neo-adjuvant (N) | 2017-09-28 | 2017-10-09 | VIDE | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100008289 |
| 160012052 | 160005748 | 1.68 | 94 | Neo-adjuvant (N) | 2018-05-29 | 2018-05-30 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | IPILIMUMAB + NIVOLUMAB | 100134400 |
| 160012053 | 160005749 | 1.65 | 61 | Palliative (P) | 2016-07-08 | 2016-07-29 | Doxorubicin + Olaratumab | 02 | null | PACLITAXEL | 100965583 |
| 160012054 | 160005750 | 1.81 | 54.8 | Palliative (P) | null | 2019-03-17 | Trial Unspecified | 02 | N | TRIAL | 100323665 |
| 160012055 | 160005751 | 1.73 | 62.75 | Palliative (P) | null | 2018-06-27 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100382666 |
| 160012058 | 160005753 | 1.77 | 59 | 03 | null | 2019-06-21 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101441215 |
| 160012059 | 160005754 | 1.85 | 100 | Palliative (P) | 2017-11-10 | 2017-11-10 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | VINORELBINE | 101348411 |
| 160012061 | 160005755 | 1.87 | 86.9 | Palliative (P) | 2018-06-21 | 2018-06-28 | Hydroxycarbamide | null | N | DOXORUBICIN + IFOSFAMIDE | 100760270 |
| 160012063 | 160005756 | 1.65 | 93.1 | Palliative (P) | 2018-03-04 | 2018-03-28 | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101035514 |
| 160012064 | 160005757 | 0 | 0 | Palliative (P) | 2018-06-20 | 2018-06-24 | RUXOLITINIB | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101487150 |
| 160012066 | 160005758 | 1.8 | 83.5 | Palliative (P) | 2017-05-09 | 2017-05-14 | Doxorubicin + Olaratumab | N | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101324365 |
| 160012067 | 160005759 | 1.6 | 72 | Palliative (P) | 2019-08-29 | 2019-08-30 | ATOMIC-MESO TRIAL | 02 | N | TRIAL | 100733181 |
| 160012068 | 160005760 | 1.75 | 102 | Palliative (P) | 2018-05-01 | 2018-06-23 | ICON8B TRIAL | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101598329 |
| 160012069 | 160005761 | 1.66 | 77.4 | Palliative (P) | null | 2019-10-27 | Ifosfamide | 01 | N | LIPOSOMAL DOXORUBICIN | 101053473 |
| 160012070 | 160005762 | null | null | Palliative (P) | 2018-07-16 | 2018-07-29 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 101159934 |
| 160012071 | 160005763 | 1.7 | 56 | Palliative (P) | 2016-07-04 | 2016-07-14 | EW EuroEwing 2012 Arm A VAI | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100001263 |
| 160012072 | 160005764 | 1.68 | 90 | Curative (C) | 2019-09-28 | 2019-09-28 | Trial Unspecified | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101051680 |
| 160012073 | 160005765 | 1.82 | 85.9 | Palliative (P) | 2016-11-10 | 2016-11-25 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101559079 |
| 160012075 | 160005766 | 1.71 | 77.6 | Palliative (P) | 2019-03-14 | 2019-03-14 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | N | DOXORUBICIN + IFOSFAMIDE | 101845743 |
| 160012077 | 160005767 | 1.82 | 73 | null | 2016-02-20 | 2016-02-23 | Doxorubicin + Ifosfamide | 02 | null | IPILIMUMAB + NIVOLUMAB | 100638902 |
| 160012078 | 160005768 | null | null | Palliative (P) | 2020-06-11 | 2020-06-11 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100084242 |
| 160012079 | 160005769 | 1.82 | 101 | Curative (C) | 2016-06-10 | 2016-06-24 | Capecitabine | 02 | N | VIDE | 100727705 |
| 160012080 | 160005770 | 0 | 20 | Neo-adjuvant (N) | 2016-09-20 | 2016-09-23 | NB HRNBL-1 MOD N7 CAV | 01 | N | ETOP 13-18 BEAT-MESO TRIAL | 100514253 |